Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JMP Securities Downgrades ERYTECH Pharma to Market Perform From Market Outperform

10/26/2021 | 06:06am EST


ę MT Newswires 2021
All news about ERYTECH PHARMA S.A.
12/01European ADRs Move Sharply Higher in Wednesday Trading
MT
11/30European ADRs Move Lower in Tuesday Trading
MT
11/30ERYTECH PHARMA S A : Secures US Patent Directed to Sequential Use of Methioninase & Aspara..
PU
11/29Erytech Pharma Gets US Patent For Methioninase, Asparaginase in Solid Tumor Treatment
MT
11/29Erytech Pharma Secures US Patent in Methioninase, Asparaginase Use for Solid Tumors -- ..
MT
11/29ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase aga..
AQ
11/17European ADRs Higher Wednesday as Credit Suisse, Barrick Gold Gain
MT
11/16European ADRs Mixed in Tuesday Morning Trading
MT
11/15ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
AQ
11/15European ADRs Move Slightly Higher in Monday Trading
MT
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 6,74 M 7,60 M 7,60 M
Net income 2021 -61,2 M -69,1 M -69,1 M
Net Debt 2021 16,1 M 18,2 M 18,2 M
P/E ratio 2021 -0,73x
Yield 2021 -
Capitalization 63,1 M 71,2 M 71,2 M
EV / Sales 2021 11,8x
EV / Sales 2022 6,77x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | ERYP | FR0011471135 | MarketScreener
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 2,26 €
Average target price 4,30 €
Spread / Average Target 90,3%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-67.93%71
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.47%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819